newsfilter
← Latest News
Business Wire·

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Announces strategic clinical trial plans for tecarfarin in patients with End-Stage Kidney Disease (ESKD) transitioning to dialysis Tecarfarin can potentially address critical treatment gaps in patients with